EHA25 VIRTUAL MEETING

Next-generation BTK Inhibitors: A challenge for ibrutinib in B-cell Malignancies? Are the next-generation Bruton’s tyrosine kinase (BTK) inhibitors acalabrutinib and zanubrutinib poised to challenge ibrutinib’s position in the management of CLL and other forms of B-cell malignancy? We didn’t get the final answer to that question at EHA25 Virtual, but there was plenty of new […]

Read More…

--> EHA25 VIRTUAL MEETING

Subcutaneous Daratumumab Improves Clinical Outcomes in the Treatment of Patients with Amyloidosis The results of the ANDROMEDA phase 3 study of SC DARA + CyBorD in patients with newly diagnosed AL amyloidosis, which were presented during the Late-Breaking abstract session at EHA25, suggest that the combination has the potential to become the new standard of […]

Read More…

--> EHA25 Virtual

Today’s late-breaking abstract session at #EHA25Virtual saw Efstathios Kastritis present exciting new data for #daratumumab in systemic light chain (AL) amyloidosis, a rare condition that can cause serious damage to multiple organs and for which there are currently no approved therapies. – In the Phase 3 ANDROMEDA trial, the addition of daratumumab subcutaneous (SC) to cyclophosphamide-bortezomib-dexamethasone (CyBorD) resulted in […]

Read More…

--> Covid-19

Dear Friends and Colleagues These are uncertain and unprecedented times, as nCoV-19 affects the health and safety of people around the world, with Europe now the epicentre of the pandemic. Our top priority during this time is to protect the well-being of our employees, clients, partners and friends and importantly to ensure our continued ability […]

Read More…

--> AML, Pre-leukaemic Clones and Precognition

Dr Chris Pallister, Managing Director of SciMed Consulting, offers his interpretation of two recent publications that provide an insight into how gene sequencing could be used to identify individuals at higher risk of developing AML, and could also predict which post-remission AML patients are most likely to relapse.  The role of non-random somatic mutations present […]

Read More…

--> Is Cancer Chemotherapy Headed for Redundancy?

It feels like we have been anticipating the transformational impact of #PrecisionMedicine on cancer treatment. During that time, the definitions and ambitions have evolved but the promise has remained largely unfulfilled. Are we now seeing the start of the revolution that may push non-specific cancer chemotherapy into redundancy? Three reports from ASCO 2018 that question the […]

Read More…

--> The Long, Winding Road to Precision Medicine in AML

It is now almost six years since Drs Sekeres and Steensma ruefully described acute myeloid leukaemia (AML) as “the Boulevard of Broken Dreams”, reflecting the catalogue of failed attempts to develop novel treatments for this intractable disease. While the treatment of many other cancers has been transformed by targeted medicines, AML has stubbornly refused to yield, […]

Read More…

--> The Future of Myeloma Diagnosis?

The University of Kansas announced earlier this month that a key research effort has resulted in a chip-based blood test for multiple myeloma which could make bone biopsies a thing of the past by using a simple blood draw instead. We think this offers an interesting – and welcome – indicator of future approaches. The treatment […]

Read More…

--> Keeping Up to Date with the Ever-Changing Face of Cancer Treatment

The recent news that KymriahTM (tisagenecleucel) has become the first chimeric antigen receptor T-cell (CAR-T) therapy to be approved by the US Food and Drug Administration (FDA) is a powerful reminder of the growing importance of immunotherapy in the fight against cancer. But while groundbreaking immunotherapy treatments like KymriahTM offer hope to patients with what […]

Read More…

-->